Validation of HRM assay was done on another 60 subjects with β-thalassemia who were either heterozygous β-thalassemia or compound heterozygous for Hb E–β-thalassemia and homozygous Hb E encountered at our ongoing thalassemia screening program and on 6 fetal specimens at prenatal diagnosis of Hb E–β-thalassemia disease.